Early this year the DHSS directed manufacturers to stop recommending spironolactone for the treatment of hypertension and idiopathic oedema. Spiroprop (spironolactone + propranolol, Searle) intended for treating hypertension was therefore withdrawn. This decision was taken because the Licensing Authority had issued new toxicity data on canrenoate. Two separate unpublished studies from a Japanese pharmaceutical company suggested that high doses of the drug caused monomyelocytic leukaemia in rats.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.